{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:28Z","timestamp":1793212108066,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H05897, 15H05898, 20K17239, 24K11605, 20H00495"],"award-info":[{"award-number":["15H05897, 15H05898, 20K17239, 24K11605, 20H00495"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008664","name":"Ono Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Elevated blood eosinophil levels in patients with chronic obstructive pulmonary disease (COPD) with or without asthma are linked to increased exacerbations and the effectiveness of inhaled corticosteroid treatment. This study aimed to delineate the inflammatory cellular properties of eosinophils in patients with asthma-COPD overlap (ACO) and eosinophilic COPD (eCOPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eosinophils were isolated from the peripheral blood of healthy volunteers, patients with non-eCOPD, and those with ACO\/eCOPD. Multi-omics analysis involving transcriptomics, proteomics, and lipidomics was performed, followed by bioinformatic data analyses. In vitro experiments using eosinophils from healthy volunteers were conducted to investigate the molecular mechanisms underlying cellular alterations in eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proteomics and transcriptomics analyses revealed cellular characteristics in overall COPD patients represented by viral infection (elevated expression of sterol regulatory element-binding protein-1) and inflammatory responses (elevated levels of IL1 receptor-like 1, Fc epsilon receptor Ig, and transmembrane protein 176B). Cholesterol metabolism enzymes were identified as ACO\/eCOPD-related factors. Gene Ontology and pathway enrichment analyses demonstrated the key roles of antiviral responses, cholesterol metabolism, and inflammatory molecules-related signaling pathways in ACO\/eCOPD. Lipidomics showed the impaired synthesis of cyclooxygenase-derived mediators including prostaglandin E2 (PGE2) in ACO\/eCOPD. In vitro assessment confirmed that IL-33 or TNF-\u03b1 stimulation combined with IL-5 and IFN-\u03b3 stimulation induced cellular signatures in eosinophils in ACO\/eCOPD. Atorvastatin, dexamethasone, and PGE2 differentially modulated these inflammatory changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>ACO\/eCOPD is associated with viral infection and an inflammatory milieu. Therapeutic strategies using statins and inhaled corticosteroids are recommended to control these pathogenic changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1445769","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:23:31Z","timestamp":1728347011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study"],"prefix":"10.3389","volume":"15","author":[{"given":"Keeya","family":"Sunata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Onozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Okuzumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Mochimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Chubachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202646","article-title":"Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense","volume":"68","author":"McDonald","year":"2013","journal-title":"Thorax"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S144108","article-title":"The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world","volume":"13","author":"Barnes","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2019","article-title":"Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue","volume":"55","author":"Jogdand","year":"2020","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30368-0","article-title":"Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study","volume":"6","author":"Suissa","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00436-2016","article-title":"What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion","volume":"48","author":"Sin","year":"2016","journal-title":"Eur Respir J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.09.004","article-title":"Blood eosinophil and neutrophil counts differentially identify frequent exacerbation in patients with COPD with physician-diagnosed asthma and COPD","volume":"70","author":"Mochimaru","year":"2021","journal-title":"Allergol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00075","article-title":"Eosinophil activation status in separate compartments and association with asthma","volume":"4","author":"Johansson","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.alit.2019.06.002","article-title":"Cysteinyl leukotriene metabolism of human eosinophils in allergic disease","volume":"69","author":"Miyata","year":"2020","journal-title":"Allergol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2012.07.048","article-title":"Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma","volume":"131","author":"Miyata","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/all.2019.74.issue-6","article-title":"Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis","volume":"74","author":"Miyata","year":"2019","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.011","article-title":"Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection","volume":"42","author":"Kearley","year":"2015","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0803379","article-title":"Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma","volume":"76","author":"Dajotoy","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jaci.2013.05.008","article-title":"Prominent role of IFN-\u03b3 in patients with aspirin-exacerbated respiratory disease","volume":"132","author":"Steinke","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32709","article-title":"Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice","volume":"118","author":"Kang","year":"2008","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079611","article-title":"Systemic CD4+ and CD8+ T-cell cytokine profiles correlate with GOLD stage in stable COPD","volume":"40","author":"Paats","year":"2012","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3443","article-title":"Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs","volume":"17","author":"Silver","year":"2016","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.jaci.2018.04.013","article-title":"Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles","volume":"141","author":"Ghebre","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/all.16215","article-title":"Distinct roles of types 1 and 2 interferons in human eosinophil regulation: A multi-omics analysis","author":"Sasaki","year":"2024","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.2.2003122","article-title":"Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease","volume":"163","author":"Aaron","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.6.2025","article-title":"Tumor necrosis factor alpha\/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium","volume":"171","author":"Slungaard","year":"1990","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.17.5397","article-title":"Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon","volume":"80","author":"Williamson","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imr.2018.286.issue-1","article-title":"The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms","volume":"286","author":"Kabata","year":"2018","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.04.005","article-title":"A novel IL-1 family cytokine, IL-33, potently activates human eosinophils","volume":"121","author":"Cherry","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2021.2020815","article-title":"Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases","volume":"59","author":"Gaurav","year":"2022","journal-title":"J Asthma"},{"key":"B31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12890-021-01423-8","article-title":"Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease","volume":"21","author":"Joo","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.012","article-title":"Multiomics analysis identified IL-4-induced IL1RL1high eosinophils characterized by prominent cysteinyl leukotriene metabolism","author":"Sunata","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00106406","article-title":"Statin use is associated with reduced mortality in COPD","volume":"29","author":"S\u00f8yseth","year":"2007","journal-title":"Eur Respir J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01798-2020","article-title":"Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study","volume":"58","author":"Schenk","year":"2021","journal-title":"Eur Respir J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000358099","article-title":"Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease","volume":"87","author":"Drozdovszky","year":"2014","journal-title":"Respiration"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.127001","article-title":"Characterization of PGE2 receptor subtypes in human eosinophils","volume":"110","author":"Mita","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.158568","article-title":"EP4 receptor as a new target for bronchodilator therapy","volume":"66","author":"Buckley","year":"2011","journal-title":"Thorax"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.8b00609","article-title":"Proteogenomic analyses of cellular lysates using a phenol-guanidinium thiocyanate reagent","volume":"18","author":"Kawashima","year":"2019","journal-title":"J Proteome Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.E113.031658","article-title":"Western blots versus selected reaction monitoring assays: time to turn the tables","volume":"12","author":"Aebersold","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02099-7","article-title":"Ultra-fast label-free quantification and comprehensive proteome coverage with narrow-window data-independent acquisition","author":"Guzman","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235932","article-title":"Optimization of data-independent acquisition mass spectrometry for deep and highly sensitive proteomic analysis","volume":"20","author":"Kawashima","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/bi400110b","article-title":"Targeted quantitation of proteins by mass spectrometry","volume":"52","author":"Liebler","year":"2013","journal-title":"Biochemistry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2014.12.012","article-title":"Mass spectrometry-based proteomic quest for diabetes biomarkers","volume":"1854","author":"Shao","year":"2015","journal-title":"Biochim Biophys Acta"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1445769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:23:33Z","timestamp":1728347013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1445769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2024.1445769"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1445769","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1445769"}}